Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

PURPOSE We conducted a phase II study evaluating pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) as second-line therapy for relapsed or refractory (rel/ref) classical Hodgkin lymphoma (cHL) (ClinicalTrials.gov identifier: NCT03618550). METHODS Transplant eligible patients with rel/ref cHL following first-line therapy were treated with two to four cycles of...

  • 123456 Profile photo of Madelyn

    really promising data of pembro-GVD in 39 relapsed Hodgkins patients, 79% had either primary refractory or early relapse. 95% of the patients made it to AutoSCT, all of whom are disease free at median f/u of 13.5 months.